文献速递心力衰竭与心肌病

螺内酯治疗急性心力衰竭的疗效与安全性:ATHENA-HF随机临床试验

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

ATHENA-HF试验在22家美国急性照护医院纳入360例急性心衰患者,随机接受高剂量螺内酯(100 mg/d)或安慰剂/低剂量螺内酯(25 mg/d)治疗96小时。

要点

  • 高剂量螺内酯(100 mg/d)治疗96小时未显著改善NT-proBNP水平
  • 临床充血评分、呼吸困难、尿量及体重变化等次要终点均无差异
  • 高钾血症及肾功能变化在两组间相似,安全性可接受

核心结论

  • 在急性心衰患者中,常规治疗基础上加用高剂量螺内酯100 mg/d治疗96小时耐受性良好,但未改善主要或次要疗效终点。

研究设计与样本

  • 双盲、安慰剂(或低剂量)对照随机临床试验,在美国22家急性照护医院纳入360例急性心衰患者,随机接受高剂量螺内酯100 mg/d或安慰剂/螺内酯25 mg/d每日治疗96小时。

主要发现

  • 两组在临床充血评分、呼吸困难评估、净尿量、净体重变化等次要终点及30天全因死亡或心衰住院率方面均无差异。
  • 24、48、72和96小时血清钾及估算肾小球滤过率变化在两组间相似。

关键数值与推荐

  • 纳入标准:急性心衰患者,既往未使用或使用低剂量螺内酯(12.5 mg或25 mg每日),NT-proBNP≥1000 pg/mL或BNP≥250 pg/mL,不限射血分数。
  • 主要终点:基线至96小时NT-proBNP水平变化。
  • 安全性终点:高钾血症及肾功能变化。

临床怎么用

  • 对于急性心衰患者,短期高剂量螺内酯(100 mg/d×96小时)未显示额外获益,不推荐仅以降低NT-proBNP为目的常规使用。
  • 该方案安全性可接受,但需关注血钾和肾功能,尤其在高危患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF. OBJECTIVE: To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone. DESIGN, SETTING, AND PARTICIPANTS: This double-blind and placebo (or low-dose)-controlled randomized clinical trial was conducted in 22 US acute care hospitals among patients with AHF who were previously receiving no or low-dose (12.5 mg or 25 mg daily) spironolactone and had NT-proBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more, regardless of ejection fraction. INTERVENTIONS: High-dose spironolactone (100 mg) vs placebo or 25 mg spironolactone (usual care) daily for 96 hours. MAIN OUTCOMES AND MEASURES: The primary end point was the change in NT-proBNP levels from baseline to 96 hours. Secondary end points included the clinical congestion score, dyspnea assessment, net urine output, and net weight change. Safety end points included hyperkalemia and changes in renal function. RESULTS: A total of 360 patients were randomized, of whom the median age was 65 years, 129 (36%) were women, 200 (55.5%) were white, 151 (42%) were black, 8 (2%) were Hispanic or Latino, 9 (2.5%) were of other race/ethnicity, and the median left ventricular ejection fraction was 34%. Baseline median (interquartile range) NT-proBNP levels were 4601 (2697-9596) pg/mL among the group treated with high-dose spironolactone and 3753 (1968-7633) pg/mL among the group who received usual care. There was no significant difference in the log NT-proBNP reduction between the 2 groups (-0.55 [95% CI, -0.92 to -0.18] with high-dose spironolactone and -0.49 [95% CI, -0.98 to -0.14] with usual care, P = .57). None of the secondary end point or day-30 all-cause mortality or heart failure hospitalization rate differed between the 2 groups. The changes in serum potassium and estimated glomerular filtration rate at 24, 48, 72, and 96 hours. were similar between the 2 groups. CONCLUSIONS AND RELEVANCE: Adding treatment with high-dose spironolactone to usual care for patients with AHF for 96 hours was well tolerated but did not improve the primary or secondary efficacy end points. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02235077.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 28700781. doi:10.1001/jamacardio.2017.2198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。